|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease显示文摘Nonalcoholic fatty liver disease (NAFLD) is highly prevalent and can result in nonalcoholic steatohepatitis (NASH) and progressive liver disease including cirrhosis and hepatocellular carcinoma. A growing body of literature implicates the peroxisome proliferators-activated receptors (PPARs) in the pathogenesis and treatment of NAFLD. These nuclear hormone receptors impact on hepatic triglyceride accumulation and insulin resistance. The aim of this review is to describe the data linking PPARα and PPARγ to NAFLD/NASH and to discuss the use of PPAR ligands for the treatment of NASH. | Eric R Kallwitz Alan McLachlan Scott J Cotler | 2008 | World Journal of Gastroenterology2008，14，1： | 34 |
| 2 | Recurrent hepatitis C virus after transplant and the importance of plasma cells on biopsy显示文摘Hepatitis C virus(HCV) is the leading indication for liver transplantation in the United States.It recurs universally after transplant but the rate of fibrosis and the development of graft failure is variable.Different donor and recipient features have been demonstrated to impact fibrosis.Plasma cell hepatitis,a histologic finding,is one feature associated with poor graft and patient outcomes.The pathogenic mechanism resulting in plasma cell hepatitis is poorly understood,with evidence suggesting a role for both the HCV and the immune system.A recent publication described plasma cell hepatitis in a larger context of immune medicated graft dysfunction in transplant recipients receiving interferon based therapy.This manuscript will highlight the topic of plasma cell hepatitis and provide commentary on the lack of recognition,the data regarding pathophysiologic mechanisms and the potential management options. | Eric R Kallwitz | 2013 | World Journal of Gastroenterology2013，19，2： | 3 |
| 3 | Metabolic syndrome after liver transplantation: Preventable illness or common consequence?显示文摘The metabolic syndrome is common after liver transplant being present in approximately half of recipients. It has been associated with adverse outcomes such as progression of hepatitis C and major vascular events. As the United States population ages and the rate of obesity increases, prevention of the metabolic syndrome in the post-transplant population deserves special consideration. Currently, the metabolic syndrome after transplant appears at least two times more common than observed rates in the general population. Specific guidelines for patients after transplant does not exist, therefore prevention rests upon knowledge of risk factors and the presence of modifiable elements. The current article will focus on risk factors for the development of the metabolic syndrome after transplant, will highlight potentially modifiable factors and propose potential areas for intervention. As in the non-transplant population, behavioral choices might have a major role. Opportunities exist in this regard for health prevention studies incorporating lifestyle changes. Other factors such as the need for immunosuppression, and the changing characteristics of wait listed patients are not modifiable, but are important to know in order to identify persons at higher risk. Although immunosuppression after transplant is unavoidable, the contribution of different agents to the development of components of the metabolic syndrome is also discussed. Ultimately, an increased risk of the metabolic syndrome after transplant is likely unavoidable, however, there are many opportunities to reduce the prevalence. | Eric R Kallwitz | 2012 | World Journal of Gastroenterology2012，18，28： | 3 |
| 4 | Sarcopenia and liver transplant: The relevance of too little muscle mass显示文摘Loss of muscle mass and function is a common occurrence in both patients with decompensated cirrhosis and those undergoing liver transplantation. Sarcopenia is associated with morbidity and mortality before and after liver transplantation. The ability of skeletal muscle mass to recover after transplant isquestionable, and long term adverse events associated with persistent sarcopenia have not been well studied. Limited data is available examining mechanisms by which decreased muscle mass might develop. It is not clear which interventions might reduce the prevalence of sarcopenia and associated health burdens. However, measures to either decrease portal hypertension or improve nutrition appear to have benefit. Research on sarcopenia in the liver transplant setting is hampered by differing methodology to quantify muscle mass and varied thresholds determining the presence of sarcopenia. One area highlighted in this review is the heterogeneity used when defining sarcopenia. The health consequences, clinical course and potential pathophysiologic mechanisms of sarcopenia in the setting of cirrhosis and liver transplantation are further discussed. | Eric R Kallwitz | 2015 | World Journal of Gastroenterology2015，21，39： | 2 |
| 5 | The histologic spectrum of liver disease in african-american,non-hispanic white,and hispanic obesity surgery patients显示文摘 | Kallwitz ER Guzman G Tencate V | | American Journal of Gastroenterology0，，： | 1 |
| 6 | Screening for hepatocellular carcinoma in clinical practice:miles to go before we sleep显示文摘 | Kallwitz E R Cotler S J | 2007 | J Clin Gastroenterol2007，41，： | 1 |
| 7 | Liver injury with fea- tures mimicking autoimmune hepatitis following the use of black cohosh显示文摘 | Guzman G Kallwitz ER Wojewoda C | 2009 | Case Report Med2009，2009，91： | 1 |
| 8 | Ethnicity and body mass index are associated with hepatitis C presentation and progression显示文摘 | Kallwitz ER Layden-Almer J Dhamija M | 2010 | Clin Gastroenterol Hepatol2010，8，1： | 1 |
| 9 | Liver enzymes and histology in obese patients with obstructive sleep apnea显示文摘 | Kallwitz ER Herdegen J Madura J | 2007 | J Clin Gastroenterol2007，41，： | 1 |
| 10 | Rebleeding rates following TIPS for variceal hemorrhage in the Viatorr era: TIPS alone versus TIPS with variceal embolization显示文摘 | Ron C. Gaba James T. Bui Scott J. Cotler Eric R. Kallwitz Olga T. Mengin Brandon K. Martinez Jaime L. Berkes Tami C. Carrillo M. Grace Knuttinen Charles A. Owens | 2010 | Hepatology International2010，，4： | 1 |
| 11 | Prevalence of Suspected Nonalcoholic Fatty Liver Disease in Hispanic/Latino Individuals Differs by Heritage显示文摘 | Eric R. Kallwitz Martha L. Daviglus Matthew A. Allison Kristen T. Emory Lihui Zhao Mark H. Kuniholm Jinsong Chen Natalia Gouskova Amber Pirzada Gregory A. Talavera Marston E. Youngblood Scott J. Cotler | 2015 | Clinical Gastroenterology and Hepatology2015，，3： | 1 |
| 12 | Liver enzymes and histology in obese patients with obstructive sleep apnea显示文摘 | Kallwitz ER Herdegen J Madura J | 2007 | J Clin Gastroenterol2007，41，10： | 1 |
| 13 | Liver enzymes and histol- ogy in obese patients with obstructive sleep apnea显示文摘 | Kallwitz ER Herdegen J Madura J | 2007 | J Clin C as- troenterol2007，41，10： | 1 |
| 14 | Liver en- zymes and histology in obese patients with obstructive sleep apnea 显示文摘 | KALLWITZ E R HERDEGEN J MADURA J | 2007 | J Clin Gastroenterol2007，41，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员